Evidence map›Paper›PMID 29712745›Full record

Trial reportHypertension (Dallas, Tex. : 1979)2018

Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial).

Brian P Shapiro, Walter T Ambrosius, Joseph L Blackshear, William C Cushman, Paul K Whelton, Suzanne Oparil, Srinivasan Beddhu, Jamie P Dwyer, Lisa H Gren, William J Kostis and 5 more

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Hypertension (Dallas, Tex. : 1979), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Brian P ShapiroFrom the Department of Cardiovascular Diseases (B.P.S., J.L.B.) shapiro.brian@mayo.edu.
Walter T AmbrosiusMayo Clinic, Jacksonville, FL; Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC (W.T.A.).
Joseph L BlackshearFrom the Department of Cardiovascular Diseases (B.P.S., J.L.B.).
William C CushmanPreventive Medicine Section, Veterans Affairs Medical Center, Memphis, TN (W.C.C.).
Paul K WheltonDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA (P.K.W.).
Suzanne OparilDepartment of Medicine, University of Alabama at Birmingham (S.O.).
Srinivasan BeddhuDepartment of Nephrology and Hypertension (S.B.).
Jamie P DwyerUniversity of Utah, Salt Lake City; Department of Nephrology, Vanderbilt University, Nashville, TN (J.P.D.).
Lisa H Grenand Department of Family and Preventative Medicine (L.H.G.).
William J KostisDepartment of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ (W.J.K.).
Michael LioudisDepartment of Nephrology and Hypertension, Cleveland Clinic, OH (M.L.).
Roberto PisoniDivision of Nephrology, Medical University of South Carolina, Charleston (R.P.).
Clive Rosendorffand James J. Peters Veterans Affairs Medical Center, Bronx, NY (C.R.).
William E Haleyand Division of Nephrology and Hypertension (W.E.H.).
SPRINT Research Group*

Funding

INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
Strengthening Stakeholder Engagement in Human Research Protections.UL1TR002003 · NCATS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KARNIK, NIRANJAN SUBHASH, MERMELSTEIN, ROBIN J. · 2016 to 2024
$33.7M
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Tufts Clinical and Translational Research InstituteUL1TR001064 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2013 to 2017
$26.4M
University of Iowa Clinical and Translational Science Program (TL1)UL1RR025755 · NCRR · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2008 to 2011
$26.3M
NCATS NIH HHS UL1 TR000005NCATS NIH HHS UL1 TR000050NCATS NIH HHS UL1 TR000073NCATS NIH HHS UL1 TR000075NCATS NIH HHS UL1 TR000093NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR001064NCATS NIH HHS UL1 TR001420NCATS NIH HHS UL1 TR001427NCATS NIH HHS UL1 TR002003NCATS NIH HHS UL1 TR002240NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1 RR025752NCRR NIH HHS UL1 RR025755NCRR NIH HHS UL1 RR025771NHLBI NIH HHS HHSN268200900040CNIGMS NIH HHS P30 GM103337
6 · The paper itself

Abstract

Intensive systolic blood pressure (SBP) control improved outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). Our objective was to expand on reported findings by analysis of baseline characteristics, primary outcomes, adverse events, follow-up blood pressure, and medication use differences by baseline SBP (tertile 1 [T1], <132; tertile 2 [T2], 132-145; and tertile 3 [T3], >145 mm Hg). Participants with higher baseline SBP tertile were more often women and older, had higher cardiovascular risk, and lower utilization of antihypertensive medications, statins, and aspirin. Achieved SBP in both treatment arms was slightly higher in T2 and T3 compared with T1 and fewer in the T3 groups achieved SBP targets compared with T1 and T2 groups. The primary composite outcome with intensive versus standard SBP treatment was reduced by 30% in T1, 23% in T2, and 17% in T3 with no evidence of an interaction (

Indexed as

Disease ManagementAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBlood Pressure DeterminationCalcium Channel BlockersDiureticsFemaleFollow-Up StudiesHumansHypertensionMaleMiddle AgedRisk FactorsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCalcium Channel BlockersDiureticsaspirinblood pressurefollow-up studieshypertensionrisk factors

Identifiers

PMID29712745
PMCPMC5945323

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.